Abstract
BackgroundMethotrexate (MTX) is the most commonly used conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA). In the phase 3 MOBILITY study (NCT01061736),1 of sarilumab in inadequate responders...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have